oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciencesoncotomsk-101Research ArticleОБЗОРЫREVIEWSПОЗИТРОНАЯ ЭМИССИОНАЯ ТОМОГРАФИЯ В ОНКОГИНЕКОЛОГИИPOSITRON EMISSION TOMOGRAPHY IN GYNECOLOGIC ONCOLOGYРыжковаД. В.RyzhkovaD. V.ryjkova@mail.ruВинокуровВ. Л.VinokurovV. L.ПавловаВ. С.PavlovaV. S.РогачевЬ. В.RogachevM. V.ФГБУ «Российский научный центр радиологии и хирургических технологий» Министерства здравоохранения России, г. Санкт-ПетербургРоссияRussian Scientific Center of Radiology and Surgical Technologies, St-PetersburgRussian FederationФГБУ «Федеральный центр сердца, крови и эндокринологии им. В. А. Алмазова» Министерства здравоохранения России, г. Санкт-ПетербургРоссияV.A. Almazov Federal Heart, Blood and Endocrinology Centre, St-PetersburgRussian FederationФГБУ «НИИ онкологии им. Н.Н. Петрова» Министерства здравоохранения России, г. Санкт-ПетербургРоссияN.N. Petrov Research Institute of OncologyRussian Federation201316022016027783Copyright © Рыжкова Д.В., Винокуров В.Л., Павлова В.С., Рогачев Ь.В., 20162016Рыжкова Д.В., Винокуров В.Л., Павлова В.С., Рогачев Ь.В.Ryzhkova D.V., Vinokurov V.L., Pavlova V.S., Rogachev M.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/101

Представленный обзор литературы посвящен анализу радиофармацевтических препаратов и эффективности применения позитронной эмиссионной томографии (ПЭТ) для диагностики, оценки распространенности и оценки эффективности злокачественныхновообразований женских половых органов. На основании результатов клинических исследований продемонстрированы диагностические возможности ПЭТ с  18F-фтордезоксиглюкозой в определении первичного опухолевого очага, оценке распространенности опухолевого процесса и эффективности противоопухолевого лечения при раке шейки и тела матки, яичников и вульвы.

The literature review is devoted to the analysis of radiopharmaceutical agents and the efficiency of positron emission tomography (PET) for diagnosis, evaluation of tumor spread and assessment of treatment response in patients with gynecological cancer. Diagnostic value of PET using18F-fluorodeoxyglucose was demonstrated in the diagnosis of primary tumor, assessment of the extent of tumor involvement and treatment response in patients with cancer of the cervix and body of the uterus, ovaries and vulva.

позитронная эмиссионная томографиязлокачественные опухоли женской половой сферыpositron emission tomographygynecological cancerReferencesГранов А.М., Тютин Л.А. Позитронная эмиссионная томография. СПб.: Фолиант, 2008. 368 с.Гранов А.М., Тютин Л.А. Позитронная эмиссионная томография. СПб.: Фолиант, 2008. 368 с.Belhocine T., De Barsy C., Hustinx R., Willems-Foidart J. Usefulness of (18)F-FDG PET in the post-therapy surveillance of endometrial carcinoma // Eur. J. Nucl. Med. Mol. Imaging. 2002. Vol. 29. P. 1132–1139.Belhocine T., De Barsy C., Hustinx R., Willems-Foidart J. Usefulness of (18)F-FDG PET in the post-therapy surveillance of endometrial carcinoma // Eur. J. Nucl. Med. Mol. Imaging. 2002. Vol. 29. P. 1132–1139.Benedet J.L., Bender H., Jones H. et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancer // Int. J. Gynecol. Obstet. 2000. Vol. 70. P. 209–262.Benedet J.L., Bender H., Jones H. et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancer // Int. J. Gynecol. Obstet. 2000. Vol. 70. P. 209–262.Bentivegna E., Uzan C., Gouy S. et al. The accuracy of FDG-PET/ CT in early-stage cervical and vaginal cancers // Gynecol. Obstet. Fertil. 2011. Vol. 39 (4). P. 193–197.Bentivegna E., Uzan C., Gouy S. et al. The accuracy of FDG-PET/ CT in early-stage cervical and vaginal cancers // Gynecol. Obstet. Fertil. 2011. Vol. 39 (4). P. 193–197.Cancer Facts & Figures. Atlanta, GA: American Cancer Society; 2005.Cancer Facts & Figures. Atlanta, GA: American Cancer Society; 2005.Chander S., Meltzer C.C., McCook B.M. Physiologic uterine uptake of FDG during menstruation demonstrated with serial combined positron emission tomography and computed tomography // Clin. Nucl. Med. 2002. Vol. 27. P. 22–24.Chander S., Meltzer C.C., McCook B.M. Physiologic uterine uptake of FDG during menstruation demonstrated with serial combined positron emission tomography and computed tomography // Clin. Nucl. Med. 2002. Vol. 27. P. 22–24.Chang T.C., Law K.S., Hong J.H. et al. Positron emission tomography for unexplained elevation of serum squamous cell carcinoma antigen levels during follow-up for patients with cervical malignancies: a phase II study // Cancer. 2004. Vol. 101. P. 164–171.Chang T.C., Law K.S., Hong J.H. et al. Positron emission tomography for unexplained elevation of serum squamous cell carcinoma antigen levels during follow-up for patients with cervical malignancies: a phase II study // Cancer. 2004. Vol. 101. P. 164–171.Cohn D.E., Dehdashti F., Gibb R.K. et al. Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer // Gynecol. Oncol. 2002. Vol. 85. P. 179–184.Cohn D.E., Dehdashti F., Gibb R.K. et al. Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer // Gynecol. Oncol. 2002. Vol. 85. P. 179–184.Dehdashti F., Grigsby P.W., Mintun M.A. et al. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 62Cu-ATSM: relationship to therapeutic response – a preliminary report // Int. J. Radiat. Oncol. Biol. Phys. 2003. Vol. 55. P. 1233–1238.Dehdashti F., Grigsby P.W., Mintun M.A. et al. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 62Cu-ATSM: relationship to therapeutic response – a preliminary report // Int. J. Radiat. Oncol. Biol. Phys. 2003. Vol. 55. P. 1233–1238.Delbeke D., Martin W.H. Positron emission tomography imaging in oncology // Radiol. Clin. North. Am. 2001. Vol. 39. P. 883–917.Delbeke D., Martin W.H. Positron emission tomography imaging in oncology // Radiol. Clin. North. Am. 2001. Vol. 39. P. 883–917.Drieskens O., Stroobants S., Gysen M. et al. Positron emission tomography with FDG in the detection of peritoneal and retroperitoneal metastases of ovarian cancer // Gynecol. Obstet. Invest. 2003. Vol. 55. P. 130–134.Drieskens O., Stroobants S., Gysen M. et al. Positron emission tomography with FDG in the detection of peritoneal and retroperitoneal metastases of ovarian cancer // Gynecol. Obstet. Invest. 2003. Vol. 55. P. 130–134.Grigsby P.W., Siegel B.A., Dehdashti F. et al. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome // J. Clin. Oncol. 2004. Vol. 22. P. 2167–2171.Grigsby P.W., Siegel B.A., Dehdashti F. et al. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome // J. Clin. Oncol. 2004. Vol. 22. P. 2167–2171.Grit K., Horn L.C., Fisher U. et al. 18F-FDG positronen-Emissions-Tomographie bei Zervixkarzinom: Erste Ergebnisse // Zbl. Gynacol. 2001. № 4. P. 123.Grit K., Horn L.C., Fisher U. et al. 18F-FDG positronen-Emissions-Tomographie bei Zervixkarzinom: Erste Ergebnisse // Zbl. Gynacol. 2001. № 4. P. 123.Gorospe L., Jover-Diaz R., Vicente-Bartulos A. et al Spectrum of PET-CT pelvic pitfalls in patients with gynecologic malignancies // Abdom. Imaging. 2012. Vol. 37 (6). P. 1041–1065.Gorospe L., Jover-Diaz R., Vicente-Bartulos A. et al Spectrum of PET-CT pelvic pitfalls in patients with gynecologic malignancies // Abdom. Imaging. 2012. Vol. 37 (6). P. 1041–1065.Havrilesky L.J., Kulasingam S.L., Matchar D.B., Myers E.R. FDGPET for management of cervical and ovarian cancer // Gynecol. Oncol. 2005. Vol. 97. P. 183–191.Havrilesky L.J., Kulasingam S.L., Matchar D.B., Myers E.R. FDGPET for management of cervical and ovarian cancer // Gynecol. Oncol. 2005. Vol. 97. P. 183–191.Hubner K.F., McDonald T.W., Niethammer J.G. et al. Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[ 18F]deoxyglucose (2-[ 18F]FDG) // Gynecol Oncol. 1993. Vol. 51. P. 197–204.Hubner K.F., McDonald T.W., Niethammer J.G. et al. Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[ 18F]deoxyglucose (2-[ 18F]FDG) // Gynecol Oncol. 1993. Vol. 51. P. 197–204.Hughes E.C. The effect of enzymes upon metabolism, storage and release of carbohydrates in normal and abnormal endometria // Cancer. 1976. Vol. 38. P. 487–502.Hughes E.C. The effect of enzymes upon metabolism, storage and release of carbohydrates in normal and abnormal endometria // Cancer. 1976. Vol. 38. P. 487–502.Jang H.J., Lee K.H., Kim Y.H. et al. The role PET for predicting prognosis in squamous cell type uterine cervical carcinoma patients // J. Nucl. Med. 2002. Vol. 43 (3). Suppl. P. 28.Jang H.J., Lee K.H., Kim Y.H. et al. The role PET for predicting prognosis in squamous cell type uterine cervical carcinoma patients // J. Nucl. Med. 2002. Vol. 43 (3). Suppl. P. 28.Kim S., Chung J.K., Kang S.B. et al. [18F]FDG PET as a substitute for second-look laparotomy in patients with advanced ovarian carcinoma // Eur. J. Nucl. Med. Mol. Imaging. 2004. Vol. 31. P. 196–201.Kim S., Chung J.K., Kang S.B. et al. [18F]FDG PET as a substitute for second-look laparotomy in patients with advanced ovarian carcinoma // Eur. J. Nucl. Med. Mol. Imaging. 2004. Vol. 31. P. 196–201.Lai C.H., Huang K.G., See L.C. et al. Restaging of recurrent cervical carcinoma with dual-phase [18F]fluoro-2-deoxy-D-glucose positron emission tomography // Cancer. 2004. Vol. 100. P. 544–552.Lai C.H., Huang K.G., See L.C. et al. Restaging of recurrent cervical carcinoma with dual-phase [18F]fluoro-2-deoxy-D-glucose positron emission tomography // Cancer. 2004. Vol. 100. P. 544–552.Lamoreaux W.T., Grigsby P.W., Dehdashti F. et al. FDG-PET evaluation of vaginal carcinoma // Int. J. Radiat. Oncol. Biol. Phys. 2005. Vol. 62. P. 733–737.Lamoreaux W.T., Grigsby P.W., Dehdashti F. et al. FDG-PET evaluation of vaginal carcinoma // Int. J. Radiat. Oncol. Biol. Phys. 2005. Vol. 62. P. 733–737.Lapela M., Leskinen-Kallio S., Varpula M. et al. Imaging of uterine carcinoma by carbon-11-methionine and PET // J. Nucl. Med. 1994. Vol. 35. P. 1618–1623.Lapela M., Leskinen-Kallio S., Varpula M. et al. Imaging of uterine carcinoma by carbon-11-methionine and PET // J. Nucl. Med. 1994. Vol. 35. P. 1618–1623.Lerman H., Metser U., Grisaru D. et al. Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT // J. Nucl. Med. 2004. Vol. 45. P. 266–271.Lerman H., Metser U., Grisaru D. et al. Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT // J. Nucl. Med. 2004. Vol. 45. P. 266–271.Ma S.Y., See L.C., Lai C.H. et al. Delayed (18)F-FDG PET for detection of paraaortic lymph node metastases in cervical cancer patients // J. Nucl. Med. 2003. Vol. 44. P. 1775–1783.Ma S.Y., See L.C., Lai C.H. et al. Delayed (18)F-FDG PET for detection of paraaortic lymph node metastases in cervical cancer patients // J. Nucl. Med. 2003. Vol. 44. P. 1775–1783.Nanni C., Rubello D., Farsad M. et al. (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients // Eur. J. Surg. Oncol. 2005. Vol. 31. P. 792–797.Nanni C., Rubello D., Farsad M. et al. (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients // Eur. J. Surg. Oncol. 2005. Vol. 31. P. 792–797.Park W., Park Y.J., Huh S.J. et al. The usefulness of MRI and PET imaging for the Detection of parametrial involvement and lymph node metastasis in patients with cervical cancer // Jpn. J. Clin. Oncol. 2005. Vol. 35. P. 260–264.Park W., Park Y.J., Huh S.J. et al. The usefulness of MRI and PET imaging for the Detection of parametrial involvement and lymph node metastasis in patients with cervical cancer // Jpn. J. Clin. Oncol. 2005. Vol. 35. P. 260–264.Picchio M., Sironi S., Messa C. et al. Advanced ovarian carcinoma: usefulness of [(18)F]FDG-PET in combination with CT for lesion detection after primary treatment // J. Nucl. Med. 2003. Vol 47. P. 77–84.Picchio M., Sironi S., Messa C. et al. Advanced ovarian carcinoma: usefulness of [(18)F]FDG-PET in combination with CT for lesion detection after primary treatment // J. Nucl. Med. 2003. Vol 47. P. 77–84.Rose P.G., Faulhaber P., Miraldi F., Abdul-Karim F.W. Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy // Gynecol. Oncol. 2001. Vol. 82. P. 17–21.Rose P.G., Faulhaber P., Miraldi F., Abdul-Karim F.W. Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy // Gynecol. Oncol. 2001. Vol. 82. P. 17–21.Saga T., Higashi T., Ishimori T. et al. Clinical value of FDG-PET in the follow up of post-operative patients with endometrial cancer // Ann. Nucl. Med. 2003. Vol. 17. P. 197–203.Saga T., Higashi T., Ishimori T. et al. Clinical value of FDG-PET in the follow up of post-operative patients with endometrial cancer // Ann. Nucl. Med. 2003. Vol. 17. P. 197–203.Schroder W., Zimmy M., Rudlowski C. et al. The role of 18-fluorodeoxyglucose positron emission tomography in diagnosis of ovarian cancer // Int. J. Gynecol. Cancer. 1999. Vol. 9. P. 117–122.Schroder W., Zimmy M., Rudlowski C. et al. The role of 18-fluorodeoxyglucose positron emission tomography in diagnosis of ovarian cancer // Int. J. Gynecol. Cancer. 1999. Vol. 9. P. 117–122.Schroder W., Zimny M., Rudlowski C. The role of 18-F-flurorodeoxyglucose position imaging tomography 18-F-FGD PET in ovarian carcinoma // Int. J. Gynecol. Cancer. 1999. Vol. 9. P. 117–122.Schroder W., Zimny M., Rudlowski C. The role of 18-F-flurorodeoxyglucose position imaging tomography 18-F-FGD PET in ovarian carcinoma // Int. J. Gynecol. Cancer. 1999. Vol. 9. P. 117–122.Singh A.K., Grigsby P.W., Dehdashti F. et al. FDG-PET lymph node staging and survival of patients with FIGO stage IIIb cervical carcinoma // Int. J. Radiat. Oncol. Biol. Phys. 2003. Vol. 56. P. 489–493.Singh A.K., Grigsby P.W., Dehdashti F. et al. FDG-PET lymph node staging and survival of patients with FIGO stage IIIb cervical carcinoma // Int. J. Radiat. Oncol. Biol. Phys. 2003. Vol. 56. P. 489–493.Smith G.T., Hubner K.F., McDonald T., Thie J.A. Cost analysis of FDG PET for managing patients with ovarian cancer // Clin. Positron Imaging. 1999. Vol. 2. P. 63–70.Smith G.T., Hubner K.F., McDonald T., Thie J.A. Cost analysis of FDG PET for managing patients with ovarian cancer // Clin. Positron Imaging. 1999. Vol. 2. P. 63–70.Son H., Khan S.M., Rahaman J. Role of FDG PET/CT in Staging of Recurrent Ovarian Cancer // J. RadioGraphics. 2011. Vol. 31. P. 569–583.Son H., Khan S.M., Rahaman J. Role of FDG PET/CT in Staging of Recurrent Ovarian Cancer // J. RadioGraphics. 2011. Vol. 31. P. 569–583.Son H., Kositwattanarerk A., Hayes M.P. et al. PET/CT Evaluation of Cervical Cancer: Spectrum of Disease // J. RadioGraphics. 2010. Vol. 30. P. 1251–1268.Son H., Kositwattanarerk A., Hayes M.P. et al. PET/CT Evaluation of Cervical Cancer: Spectrum of Disease // J. RadioGraphics. 2010. Vol. 30. P. 1251–1268.Takekuma M., Maeda M., Ozawa T. et al. Positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer // Int. J. Clin. Oncol. 2005. Vol. 10. P. 177–181.Takekuma M., Maeda M., Ozawa T. et al. Positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer // Int. J. Clin. Oncol. 2005. Vol. 10. P. 177–181.Tjalma W.A., Carp L., De Beeck B.O. False-positive positron emission tomographic scan and computed tomography for recurrent vaginal cancer: pitfalls of modern imaging techniques // Gynecol. Oncol. 2004. Vol. 92. P. 726–728.Tjalma W.A., Carp L., De Beeck B.O. False-positive positron emission tomographic scan and computed tomography for recurrent vaginal cancer: pitfalls of modern imaging techniques // Gynecol. Oncol. 2004. Vol. 92. P. 726–728.Torizuka T., Kanno T., Futatsubashi M., et al. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET // J. Nucl. Med. 2003. Vol. 44. P. 1051–1056.Torizuka T., Kanno T., Futatsubashi M., et al. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET // J. Nucl. Med. 2003. Vol. 44. P. 1051–1056.Turlakow A., Yeung H.W., Salmon A.S. et al. Peritoneal carcinomatosis: role of (18)F-FDG PET // J. Nucl. Med. 2003. Vol. 44. P. 1407–1412.Turlakow A., Yeung H.W., Salmon A.S. et al. Peritoneal carcinomatosis: role of (18)F-FDG PET // J. Nucl. Med. 2003. Vol. 44. P. 1407–1412.Umesaki N., Tanaka T., Miyama M. et al. Positron emission tomography using 2-[(18)F] fluoro-2-deoxy-D-glucose in the diagnosis of uterine leiomyosarcoma: a case report // Clin. Imaging. 2001. Vol. 25. P. 203–205.Umesaki N., Tanaka T., Miyama M. et al. Positron emission tomography using 2-[(18)F] fluoro-2-deoxy-D-glucose in the diagnosis of uterine leiomyosarcoma: a case report // Clin. Imaging. 2001. Vol. 25. P. 203–205.Umesaki N., Tanaka T., Miyama M. et al. Positron emission tomography with (18)F-fluorodeoxyglucose of uterine sarcoma: a comparison with magnetic resonance imaging and power Doppler imaging // Gynecol. Oncol. 2001. Vol. 80. P. 372–377.Umesaki N., Tanaka T., Miyama M. et al. Positron emission tomography with (18)F-fluorodeoxyglucose of uterine sarcoma: a comparison with magnetic resonance imaging and power Doppler imaging // Gynecol. Oncol. 2001. Vol. 80. P. 372–377.Viswanathan A., Kirisits C., Erickson B.E., Pötter R. Gynecologic Radiation Therapy – Novel Approaches to Image-Guidance and Management. Springer Verlag, 2010. 308 p.Viswanathan A., Kirisits C., Erickson B.E., Pötter R. Gynecologic Radiation Therapy – Novel Approaches to Image-Guidance and Management. Springer Verlag, 2010. 308 p.Wong T.Z., Jones E.L., Coleman R.E. Positron emission tomography with 2-eoxy-2-[(18)F]fluoro-D-glucose for evaluating local and distant disease in patients with cervical cancer // Mol. Imaging Biol. 2004. Vol. 6. P. 55–62.Wong T.Z., Jones E.L., Coleman R.E. Positron emission tomography with 2-eoxy-2-[(18)F]fluoro-D-glucose for evaluating local and distant disease in patients with cervical cancer // Mol. Imaging Biol. 2004. Vol. 6. P. 55–62.Yen T.C., Lai C.H., Wu Y.H. et al. Glut-1 expression in invasive cervical cancer // Eur. J. Nucl. Med. Mol. Biol. 2002. Vol. 29 (Suppl). P. 266.Yen T.C., Lai C.H., Wu Y.H. et al. Glut-1 expression in invasive cervical cancer // Eur. J. Nucl. Med. Mol. Biol. 2002. Vol. 29 (Suppl). P. 266.Yen T.C., See L.C., Chang T.C. et al. Defining the priority of using 18F-FDG PET for recurrent cervical cancer // J. Nucl. Med. 2004. Vol. 45. P. 1632–1639.Yen T.C., See L.C., Chang T.C. et al. Defining the priority of using 18F-FDG PET for recurrent cervical cancer // J. Nucl. Med. 2004. Vol. 45. P. 1632–1639.

The authors declare that there are no conflicts of interest present.